Bernstein analysts Tim Anderson and Ronny Gal are out this morning with a note to investors suggesting that generic Lipitor could be delayed because of manufacturing problems at Ranbaxy, the first generic drug maker to file with the Food and Drug Administration and the company with whom Pfizer settled.